Subcommittees

Strategies for Commercialization Track Subcommittee

William Milligan, BSc – Chair
Steminent Biotherapeutics Inc.
Vancouver, BC, Canada

Julie Allickson, PhD, MS , MT(ASCP)
Wake Forest Institute for Regenerative Medicine
Winston-Salem, NC, United States

Gerhard Bauer, PhD
University of California Davis
Sacramento, CA, United States

Dawn Driscoll, MBA, PhD
Isopogen Pty Ltd.
Perth, Australia

Simon Ellison, MBA
Cell and Gene Therapy Catapult
London, United Kingdom

Roberto Fanganiello, PhD
R-Crio
Sao Paulo Brazil

Miguel Forte, MD, PhD
TxCell
Valbonne, France

Uri Hertzberg, PhD, MBA
Celegene
New York, NY, United States

Ohad Karnieli, MBA, PhD
ATVIO Biotechnology
Tivon, Israel

Bruce Levine, PhD
University of Pennsylvania
Philadelphia, PA, United States

Willie Mays, PhD
Athersys
Cleveland, OH, United States

Mike Mendicino, PhD
Hybrid Concepts International
New York, NY, United States

Julie Murrell, PhD
MilliporeSigma
Bedford, MA, United States

Colin Lee Novick, BA
CJ Partners Inc
Tokyo, Japan

Quality and Operations Track Subcommittee

Rosemarie Bell, B.App.Sc, MASM – Co-Chair
QIMR Berghofer Medical Research Institute
Brisbane, Australia

Sowmya Viswanathan, PhD – Co-Chair
University Health Network, University of Toronto
Toronto, ON, Canada

Shirley Bartido, PhD, MBA
Cellectis Inc.
New York, NY, United States

Christopher Bravery, PhD
Consulting on Advanced Biologicals Ltd.
London, United Kingdom

Heather Garrity, BSc
Dana Farber Cancer Institute
Boston, MA, United States

Aisha Khan, MSc, MBA
University of Miami
Miami, FL, United States

Nadim Mahmud, MD, PhD
University of Illinois Hospital and Health Sciences System
Chicago, IL, United States

Gabrielle O’Sullivan, PhD
Royal Prince Alfred Hospital
Sydney, Australia